Pharmacokinetics and Bioequivalence of Fluconazole Capsules Manufactured in France and China in Healthy Chinese Participants: Open-Label, Randomized, Single-Dose, 2-Way, Crossover Bioequivalence Study Under Fasted and Fed Conditions.

Chen, Naihan; He, Qing; Ma, Ying; Liu, Shixue; Wei, Hua; Peng, Ao

Chen, Naihan; He, Qing; Ma, Ying; Liu, Shixue; Wei, Hua; Peng, Ao.

Afiliação

Chen N; Clinical Pharmacology, Development China, Pfizer Pharmaceutical Ltd., Beijing, China.
He Q; Wuxi People's Hospital, Wuxi, Jiangsu, China.
Ma Y; Clinical Development, Development China, Pfizer Pharmaceutical Ltd., Shanghai, China.
Liu S; China Statistics, Global Biometrics and Data Management, Pfizer Pharmaceutical Ltd., Shanghai, China.
Wei H; Clinical Pharmacology, Development China, Pfizer Pharmaceutical Ltd., Shanghai, China.
Peng A; Clinical Pharmacology, Development China, Pfizer Pharmaceutical Ltd., Beijing, China.

Clin Pharmacol Drug Dev ; 12(6): 572-578, 2023 06.

Article em En | MEDLINE | ID: mdl-37036155

Assuntos

Fluconazol; Humanos; Área Sob a Curva; Disponibilidade Biológica; Estudos Cross-Over; População do Leste Asiático; Fluconazol/farmacocinética; Equivalência Terapêutica

Palavras-chave

bioequivalence; clinical trial; fluconazole; healthy Chinese; pharmacokinetics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fluconazol Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google